Partnership between academia and industry to refine a comprehensive patient-reported medication adherence measure tool for physicians and payers

The objective was to refine and adopt the Medication Adherence Reasons Scale (MAR-Scale), a comprehensive patient-reported measure of medication adherence, to improve medication utilization and patient outcomes among physicians and payers

Demographic characteristics of respondents age 18+ years by smoking status.

<p>Comparison between the 2010 National Health Interview Survey (NHIS) and the 2011 National Health and Wellness Survey (NHWS).</p><p><i>Note</i>. Presented are row percentages (summing to 100% across columns), and in brackets are 95% confidence intervals for the row percentages. Data in this table are based on two questions in the NHIS: “Have you smoked at least 100 cigarettes in your entire life?” and “Do you now smoke cigarettes every day, some days, or not at all?”</p>†<p>Source: Schiller et al., 2012 <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0093014#pone.0093014-Schiller1" target="_blank">[15]</a>. Race/ethnicity was recoded from variables (HISPAN_I; RACERPI2) to create mutually exclusive groups, summing to total adults. Percentages were from Table XV. Confidence intervals were manually calculated based on the standard errors as noted in Table XV; they could not be determined for non-Hispanic Asian and non-Hispanic Other, as standard errors were not available for these subgroups.</p>‡<p>Current smokers have smoked at least 100 cigarettes in their lifetime and still currently smoke. Every day smokers are current smokers who smoke every day, while some day smokers are current smokers who smoke on some days.</p>‡‡<p>Former smokers are persons who have smoked at least 100 cigarettes in their lifetime but currently do not smoke at all.</p>‡‡‡<p>Nonsmokers are persons who have never smoked at least 100 cigarettes in their lifetime.</p>§<p>Current smokers defined as those who responded, “Yes, I smoke” or, “Yes, but I am trying to quit.”</p>§§<p>Former smokers defined as those who responded, “No, I quit smoking” or, “No, I am in the process of quitting.”</p>§§§<p>Nonsmokers defined as those who responded, “No” to the question, “Have you ever smoked cigarettes?”</p

Comparison of characteristics across smoking groups based on the 2011 National Health and Wellness Survey (NHWS).

<p><i>Note</i>. Superscripts represent columns whose percentage is significantly different from the column (A) at p<.05. The reference group for statistical tests was column A, Current Smokers. Superscripts for significant differences across columns B–C only are not shown. SD  =  standard deviation.</p>†<p>Respiratory/cardiovascular conditions include diagnoses of any of the following: COPD, asthma, emphysema, chronic bronchitis, hypertension, and heart attack.</p>‡<p>Mental health conditions include any of the following: diagnoses of bipolar disorder, depression, GAD, anxiety, and OCD; and experiences of insomnia and alcoholism.</p>‡‡<p>Headache/migraine conditions include diagnoses of any of the following: headache and migraine.</p

Adjusted health outcomes in patients with AF and matched controls.

<p>Adjusted health outcomes in patients with AF and matched controls.</p

Overall Humanistic Burden as a function of AF, demographics, comorbidities, and behavioral factors.

<p><i>Note.</i> Nonsignificant predictors of burden are not presented above: non-white; single; divorced/widowed/separated; college education or higher; household income: $25,000 to$49,999, $50,000 to$74,999, and decline to answer; uninsured; BMI: overweight. Reference groups include: non-AF matched controls, male, white, married/living with partner, less than college education, household income:<$25,000, insured, BMI: underweight/normal, unemployed, not exercising, not currently smoking, not using alcohol, comorbidity count of 0, and CHADS2 low risk. Standardized estimates and residual variances are shown. Topmost indicators per factor set the scale. Dichotomous indicators include “(0/1).” *p<0.05. **p<0.01. ***p<0.001. No p-values are available for the scale setters and categorical residuals.</p

Adjusted healthcare resource use and depression, pain, and insomnia, in patients with AF and matched controls.

<p>Adjusted healthcare resource use and depression, pain, and insomnia, in patients with AF and matched controls.</p

Characteristics of patients with AF and matched controls.

<p>Characteristics of patients with AF and matched controls.</p

Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study

<p><i>Objective</i>: This study examined plaque psoriasis (PsO) patient characteristics across injectable biologics. <i>Methods</i>: Data were collected from 400 US dermatologists randomly selecting five charts each for patients with PsO (patient <i>n</i>  =  2000): adalimumab (ADA; <i>n</i>  =  447), etanercept (ETA; 539), ustekinumab (UST) 45 mg (511) and UST 90 mg (503). Physicians had to have been in practice 2–30 years, managing 10+  patients (5 + with biologics for PsO). Generalized estimating equation models, weighted according to inverse probability of patient selection and accounting for patient correlation within physicians, examined patient measures as a function of treatment (UST 90 mg = reference). <i>Results</i>: Patients on UST 90 mg had higher odds of weighing  >100 kg (adjusted mean  =  34.4%) vs. ADA (10.9%), ETA (5.5%) or UST 45 mg (6.8%), greater body surface affected and higher odds of severe PsO prior to treatment and higher odds of prior biologics use. Mean prior biologics used was higher with UST 90 mg versus ADA or ETA. Number of comorbidities was higher with UST 90 mg versus ETA or UST 45 mg. <i>Conclusions</i>: Among biologics-treated patients with PsO, UST 90 mg appears to be used in patients with greater weight, baseline severity and prior biologics experience than ADA, ETA or UST 45 mg. UST 90 mg is used in patients with more comorbidities than other treatments except ADA.</p